Primary extramedullary spinal melanoma mimicking spinal meningioma: A case report and literature review

July 2014
Oncology Letters;2014, Vol. 8 Issue 1, p339
Academic Journal
Primary spinal melanoma is a rare lesion, which occurs throughout the cranial and spinal regions, however, is primarily observed in the middle or lower thoracic spine. The clinical features of primary spinal melanoma are complex and unspecific, resulting in a high misdiagnosis rate. In the present case report, a rare case of spinal melanoma exhibiting the dural tail sign and mimicking spinal meningioma is reported. The initial diagnosis, using magnetic resonance imaging (MRI), was unclear. Thus, melanin-containing tumors and spinal meningioma should have been considered in the differential diagnosis. The tumor was completely resected using a standard posterior midline approach, which was followed by chemotherapy. Subsequent to the surgery, the patient was discharged with improved motor capacity and a follow-up MRI scan showed no recurrence after six months. The present study demonstrates that it is critical for neurosurgeons to focus on increasing the accuracy of initial diagnoses in order to make informed decisions regarding the requirement for surgical resection. The present case report presents the clinical, radiological and pathological features of primary extramedullary spinal melanoma mimicking spinal meningioma to emphasize the importance of early identification and diagnosis.


Related Articles

  • Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Hölzel, Michael; Bovier, Anton; Tüting, Thomas // Nature Reviews Cancer;May2013, Vol. 13 Issue 5, p365 

    Immunotherapies, signal transduction inhibitors and chemotherapies can successfully achieve remissions in advanced stage cancer patients, but durable responses are rare. Using malignant melanoma as a paradigm, we propose that therapy-induced injury to tumour tissue and the resultant inflammation...

  • BRAF-V600 Mutations Have No Prognostic Impact in Stage IV Melanoma Patients Treated with Monochemotherapy. Meckbach, Diana; Keim, Ulrike; Richter, Sabina; Leiter, Ulrike; Eigentler, Thomas K.; Bauer, Jürgen; Pflugfelder, Annette; Büttner, Petra; Garbe, Claus; Weide, Benjamin // PLoS ONE;Feb2014, Vol. 9 Issue 2, p1 

    Background: The impact of BRAF tumor mutations on the natural course of disease of melanoma patients is controversial. Patients and Methods: We analyzed the mutational status and overall survival of 215 patients receiving treatment with dacarbazine or temozolomide. All patients who started...

  • One is always nearer by not keeping still. Lees, Andrew // Brain: A Journal of Neurology;12/1/2015, Vol. 138 Issue 12, p3822 

    No abstract available.

  • A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma. Hersh, E. M.; Del Vecchio, M.; Brown, M. P.; Kefford, R.; Loquai, C.; Testori, A.; Bhatia, S.; Gutzmer, R.; Conry, R.; Haydon, A.; Robert, C.; Ernst, S.; Homsi, J.; Grob, J. J.; Kendra, K.; Agarwala, S. S.; Li, M.; Clawson, A.; Brachmann, C.; Karnoub, M. // Annals of Oncology;Nov2015, Vol. 26 Issue 11, p2267 

    Background: The efficacy and safety of nab-paclitaxel versus dacarbazine in patients with metastatic melanoma was evaluated in a phase III randomized, controlled trial. Patients and methods: Chemotherapy-naïve patients with stage IV melanoma received nab-paclitaxel 150 mg/m² on days 1, 8,...

  • Identification of Locally Advanced Rectal Cancer with Low Risk of Local Recurrence. Wang, Qiao-Xuan; Li, Shao-Hua; Zhang, Xu; Xie, Lan; Cai, Pei-Qiang; An, Xin; Pan, Zhi-Zhong; Ding, Pei-Rong // PLoS ONE;Jan2015, Vol. 10 Issue 1, p1 

    Background: The routine application of neoadjuvant chemoradiotherapy for T3N0 rectal cancer remains controversial. The aim of this study was to use clinical, Magnetic resonance imaging, and pathological parameters to identify a subgroup of patients with low risk of local recurrence who might be...

  • Regional Administration of Recombinant Tumour Necrosis Factor-α in Cancer, with Special Reference to Melanoma. Lejeune, F.; Liénard, D.; Eggermont, A. // BioDrugs;1998, Vol. 9 Issue 3, p211 

    Recombinant tumour necrosis factor-α (rTNFα) possesses the unique property of activating and selectively destroying the tumour-associated microvasculature. Systemic application of rTNFα has shown that the maximum tolerated dose (MTD) is 10 times lower than the efficient dose in animals....

  • Simulants of malignant melanoma. Piérard, Gérald E.; Piérard-Franchimont, Claudine; Delvenne, Philippe // Oncology Reviews;2015, Vol. 9 Issue 1, p23 

    During the recent period, dermoscopy has yielded improvement in the early disclosure of various atypical melanocytic neoplasms (AMN) of the skin. Beyond this clinical procedure, AMN histopathology remains mandatory for establishing their precise diagnosis. Of note, panels of experts in AMN...

  • Ipilimumab had dose-dependent effect in treatment of advanced melanoma.  // Hem/Onc Today;1/25/2010, Vol. 11 Issue 2, p32 

    The article focuses on a phase-2 trial that found that ipilimumab demonstrated a dose-depended effect in patients with advanced melanoma.

  • Trials Planned for Compounds Targeting Melanoma Protein. Kingman, Sharon // BioWorld International;4/29/2009, Vol. 14 Issue 17, p1 

    This article discusses research being done on a range of drug candidates for the treatment malignant melanoma. It references a study led by Caroline Springer which appeared in the April 23, 2009 issue of "The Journal of Medicinal Chemistry." It is noted that the candidate compounds belong to a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics